CLL/SLL
Conditions
Keywords
CLL/SLL, Lisaftoclax, APG-2575
Brief summary
This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.
Detailed description
The patients with newly diagnosed CLL/SLL, who have met all required eligibility criteria, will be randomized to the investigational group (Lisaftoclax in combination with Acalabrutinib) or the control group (immunochemotherapy, CIT).
Interventions
QD, oral administration, every 28 days for a dosing cycle.
DRUGAcalabrutinib
BID, oral administration, every 28 days for a dosing cycle.
DRUGFludarabine
Every 28 days for a treatment cycle, administration of 6 cycles.
DRUGCyclophosphamide，CTX
Every 28 days for a treatment cycle, administration of 6 cycles.
DRUGRituximab
Every 28 days for a treatment cycle, administration of 6 cycles.
DRUGChlorambucil
Every 28 days for a treatment cycle, administration of 6 cycles.
Sponsors
Ascentage Pharma Group Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. CLL/SLL must be diagnosed according to the IWCLL NCI-WG Guidelines (2018 edition) and meet at least one of the criteria requiring treatment. 2. With a measurable disease. 3. ECOG score 0-2. 4. QTcF interval: ≤450ms in males, ≤470ms in females. 5. Adequate bone marrow function independent of growth factor support. 6. Adequate liver, kidney and coagulation function. 7. Males and females of childbearing potential, and their partners voluntarily use effective contraceptive measures throughout the treatment and for at least three months after the last dose of the study drug. Male patients must avoid donation from the first dose of the study drug to three months after the last dose of the study drug. 8. Female patients of childbearing potential have negative serum pregnancy test results within 14 days prior to the first dose of the study drug. 9. Patients must be able to understand and voluntarily sign an informed consent form approved by the Ethics Committee (EC) before commencing any screening or study specific procedures. 10. Must be willing and able to complete research procedures and follow-up examinations.
Exclusion criteria
1. Any previous CLL specific treatment. 2. Failure to fully recover adequately from prior surgical procedures at the discretion of the investigator. Patients who receive a major surgery within 28 days prior to the first dose of the study drug or who receive a minor surgery (excluding biopsy) within 14 days prior to the initiation of the study. 3. Presence of significant cardiovascular disease within 6 months prior to study entry. 4. A history of significant kidney, neurological, psychiatric, pulmonary, endocrine, metabolic, immune, cardiovascular, or liver disease, which will have an adverse effect on the patient if he/she participates in the study, at the discretion of the investigator. 5. Patients who require warfarin or other anticoagulants or active hemorrhage occur within 2 months before study entry. 6. Known to have hypersensitivity to the drug ingredient or its analogues. 7. Pregnant or lactating female patients and patients who are expected to become pregnant during the study period or within 3 months after the last dose. 8. Patients who have history of other active malignant tumor other than CLL/SLL within 3 years before study entry. 9. With a malabsorption syndrome or other conditions unsuitable for enteral administration. 10. Other clinically significant uncontrolled symptoms. 11. With primary active autoimmune disease and connective tissue disease. 12. Any other circumstances or conditions that would, at the discretion of the investigator, make the patient unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progress Free Survival (PFS) | Up to 1 year | PFS is defined as the time from randomization to disease progression(PD) or death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Up to 1 year | ORR is defined as the proportion of patients who have achieved CR, CRi or PR. |
| Minimal Residual Disease (MRD) negativity rate | Up to 1 year | To observe the proportion of patients with MRD negativity in bone marrow, peripheral blood, either or both. |
| Safety evaluation based on the adverse event concurrence | Up to 1 year | Number of treatment emergent adverse events (TEAEs) and treatment related adverse events (TRAEs) will be evaluated. |
Countries
China
Contacts
Primary ContactYifan Zhai, M.D., Ph.D.
Backup ContactBo Huang, M.D.
Outcome results
None listed